AU2011313853A1 - Substituted benzamides and their uses - Google Patents

Substituted benzamides and their uses Download PDF

Info

Publication number
AU2011313853A1
AU2011313853A1 AU2011313853A AU2011313853A AU2011313853A1 AU 2011313853 A1 AU2011313853 A1 AU 2011313853A1 AU 2011313853 A AU2011313853 A AU 2011313853A AU 2011313853 A AU2011313853 A AU 2011313853A AU 2011313853 A1 AU2011313853 A1 AU 2011313853A1
Authority
AU
Australia
Prior art keywords
methyl
compound
optionally substituted
pyridinyl
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011313853A
Other languages
English (en)
Inventor
Muriel Bonnet
Denise Chan
Amato Giaccia
Michael Patrick Hay
Edwin Lai
Olga Razorenova
Connie Sun
Ray Tabibiazar
Po-Wai Yuen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auckland Uniservices Ltd
Aravive Biologics Inc
Leland Stanford Junior University
Original Assignee
Auckland Uniservices Ltd
Leland Stanford Junior University
Ruga Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auckland Uniservices Ltd, Leland Stanford Junior University, Ruga Corp filed Critical Auckland Uniservices Ltd
Publication of AU2011313853A1 publication Critical patent/AU2011313853A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2011313853A 2010-10-11 2011-10-10 Substituted benzamides and their uses Abandoned AU2011313853A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US39195810P 2010-10-11 2010-10-11
US61/391,958 2010-10-11
US201161434976P 2011-01-21 2011-01-21
US61/434,976 2011-01-21
US201161475549P 2011-04-14 2011-04-14
US61/475,549 2011-04-14
PCT/US2011/055624 WO2012051117A2 (en) 2010-10-11 2011-10-10 Substituted benzamides and their uses

Publications (1)

Publication Number Publication Date
AU2011313853A1 true AU2011313853A1 (en) 2013-05-02

Family

ID=45938912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011313853A Abandoned AU2011313853A1 (en) 2010-10-11 2011-10-10 Substituted benzamides and their uses

Country Status (10)

Country Link
US (2) US9085570B2 (enExample)
EP (1) EP2627324A4 (enExample)
JP (1) JP2013539786A (enExample)
KR (1) KR20140027907A (enExample)
CN (1) CN103327972A (enExample)
AU (1) AU2011313853A1 (enExample)
BR (1) BR112013008898A2 (enExample)
CA (1) CA2814503A1 (enExample)
WO (1) WO2012051117A2 (enExample)
ZA (1) ZA201302854B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150559B2 (en) * 2011-05-19 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Anti-proliferative compounds and methods for using the same
HK1207301A1 (en) 2012-04-12 2016-01-29 The Board Of Trustees Of The Leland Stanford Junior University Substituted benzamides and their uses
WO2013182612A1 (en) 2012-06-07 2013-12-12 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2015078799A1 (en) * 2013-11-27 2015-06-04 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
US20160318897A1 (en) 2013-12-18 2016-11-03 Basf Se Azole compounds carrying an imine-derived substituent
WO2016202935A1 (en) 2015-06-19 2016-12-22 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
CN116462606B (zh) * 2022-01-12 2025-11-28 南京宁丹新药技术股份有限公司 一类酰胺衍生化合物及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CA2186371A1 (en) 1994-03-25 1995-10-05 Robert T. Foster Enhancement of the efficacy of dihydropyridines by deuteration
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
SG126006A1 (en) 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
SK14922003A3 (sk) * 2001-06-07 2005-04-01 Eli Lilly And Company Modulátory receptorov aktivovaných proliferátormi peroxizómov (PPAR)
US7235558B2 (en) * 2002-06-06 2007-06-26 Sanofi-Aventis Deutschland Gmbh Inhibitors of the GPIb—vWF interaction, their preparation and use
EP1369420A1 (en) * 2002-06-06 2003-12-10 Aventis Pharma Deutschland GmbH Inhibitors of the GPib - vWF interaction
AU2003900207A0 (en) * 2003-01-17 2003-01-30 Fujisawa Pharmaceutical Co., Ltd. New compounds
TW200505446A (en) 2003-01-17 2005-02-16 Fuj Isawa Pharmaceutical Co Ltd Inhibitor of cox
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
WO2008112156A1 (en) 2007-03-08 2008-09-18 Altiris Therapeutics Chemokine receptor modulators
WO2009097113A2 (en) 2008-01-28 2009-08-06 New York University Oxazole and thiazole compounds as b-catenin modulators and uses thereof
WO2009114552A1 (en) * 2008-03-10 2009-09-17 The Board Of Trustees Of The Leland Stanford Junior University Heteroaryl compounds, compositions, and methods of use in cancer treatment
EP3135672B9 (en) 2008-10-10 2020-05-20 VM Discovery, Inc. Compositions and methods for treating alcohol use disorders, pain and other diseases
EP2379513A1 (en) * 2008-12-30 2011-10-26 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as raf kinase inhibitors
ES2547072T3 (es) * 2009-07-21 2015-10-01 The Board Of Trustees Of The Leland Stanford Junior University Heteroaril benzamidas, composiciones y métodos de utilización
EP2305643A1 (en) * 2009-10-02 2011-04-06 Ikerchem, S.L. New histone deacetylase inhibitors based simultaneously on trisubstituted 1h-pyrroles and aromatic and heteroaromatic spacers
WO2012100223A1 (en) * 2011-01-21 2012-07-26 John Irwin Synthetic lethal targeting of glucose transport
US9150559B2 (en) * 2011-05-19 2015-10-06 The Board Of Trustees Of The Leland Stanford Junior University Anti-proliferative compounds and methods for using the same
HK1207301A1 (en) * 2012-04-12 2016-01-29 The Board Of Trustees Of The Leland Stanford Junior University Substituted benzamides and their uses

Also Published As

Publication number Publication date
WO2012051117A3 (en) 2012-06-14
KR20140027907A (ko) 2014-03-07
WO2012051117A2 (en) 2012-04-19
BR112013008898A2 (pt) 2016-06-28
US20140024649A1 (en) 2014-01-23
US20150329503A1 (en) 2015-11-19
CA2814503A1 (en) 2012-04-19
EP2627324A4 (en) 2014-05-07
JP2013539786A (ja) 2013-10-28
CN103327972A (zh) 2013-09-25
US9085570B2 (en) 2015-07-21
ZA201302854B (en) 2014-07-25
EP2627324A2 (en) 2013-08-21

Similar Documents

Publication Publication Date Title
AU2011313853A1 (en) Substituted benzamides and their uses
JP7373992B2 (ja) 過剰増殖性疾患の治療のための置換ピラゾール化合物およびそれらの使用方法
EP3207031B1 (en) Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
CA2813708A1 (en) Arylamide derivatives as ttx-s blockers
MX2013002431A (es) Nuevos compuestos y composiciones para la inhibicion de nampt.
WO2009114552A1 (en) Heteroaryl compounds, compositions, and methods of use in cancer treatment
US9296732B2 (en) Substituted benzamides and their uses
CA2870992A1 (en) Amide derivatives as ttx-s blockers
BR112019017567A2 (pt) Derivados de 1,4,6-trissubstituído-2-alquil-1h-benzo[d]imidazol como inibidores da di-hidro-orotato oxigenase
CA2887887C (en) Pyrazolopyridine derivatives as ttx-s blockers
TW202021956A (zh) 視黃酸誘導基因"rig-i"途徑之活化劑及其使用方法
CN102341373A (zh) 作为kcnq2/3调节剂的取代的2-巯基-3-氨基吡啶
EP2456435B1 (en) Heteroaryl benzamides, compositions and methods of use
CA3226387A1 (en) Rock2 inhibitors and uses thereof
KR20110005277A (ko) 이미노피리딘 유도체 및 그 용도
CN101180055A (zh) 用于治疗疾病的包含二芳基脲的组合治疗
HK1171190B (en) Heteroaryl benzamides, compositions and methods of use
CN104003990A (zh) 杂环胺类Hedgehog信号通路抑制剂

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ: GIACCIA, AMATO; LAI, EDWIN; RAZORENOVA, OLGA; CHAN, DENISE; HAY, MICHAEL PATRICK; BONNET, MURIEL; SUN, CONNIE; TABIBIAZAR, RAY AND YUEN, PO-WAI.

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application